Base de dados : MEDLINE
Pesquisa : D20.777.500 [Categoria DeCS]
Referências encontradas : 678 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 68 ir para página                         

  1 / 678 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28376984
[Ti] Título:Insulin: Almost a Century of Lifesaving.
[So] Source:Consult Pharm;32(4):190-198, 2017 Apr 01.
[Is] ISSN:0888-5109
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The identification and purification of insulin in 1922 changed life for individuals with type 1 diabetes mellitus (T1DM). Its discovery was, to a certain extent, serendipitous. Although medical researchers suspected that some type of hormone was responsible for carbohydrate metabolism, by the end of the 19th century they had made little progress. When World War I broke out, efforts stalled. A somewhat cantankerous group of Canadian researchers led by Frederick Grant Banting, a surgeon, are credited with insulin's discovery. Their initial research was discredited and criticized for poor technique. Regardless, they persevered, and in January 1922 they successfully treated their first patient. A mere nine months later, collaboration between the University of Toronto and Eli Lilly Company made insulin available in North America. Derived from beef and pork pancreases, the 40 unit/mL product little resembled today's more refined human insulin. While insulin is indispensable to individuals with T1DM, it is also used or being studied for several different conditions. Some researchers have dubbed Alzheimer's disease "type 3 diabetes" because of similar aberrations in the blood-brain barrier and protein deposits.
[Mh] Termos MeSH primário: Pesquisa Biomédica/história
Diabetes Mellitus/história
Insulina/história
[Mh] Termos MeSH secundário: Doença de Alzheimer/epidemiologia
Doença de Alzheimer/fisiopatologia
Animais
Diabetes Mellitus/tratamento farmacológico
Diabetes Mellitus/epidemiologia
Diabetes Mellitus/fisiopatologia
Indústria Farmacêutica/história
Indústria Farmacêutica/organização & administração
História do Século XX
Seres Humanos
Insulina/uso terapêutico
Extratos Pancreáticos/história
Extratos Pancreáticos/farmacologia
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 0 (Pancreatic Extracts)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170619
[Lr] Data última revisão:
170619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE
[do] DOI:10.4140/TCP.n.2017.190


  2 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28161789
[Au] Autor:Zdenkowski N; Radvan G; Pugliese L; Charlton J; Oldmeadow C; Fraser A; Bonaventura A
[Ad] Endereço:Department of Medical Oncology, Calvary Mater Newcastle Hospital, 2 Edith St, Waratah, NSW, 2298, Australia. nick.zdenkowski@newcastle.edu.au.
[Ti] Título:Treatment of pancreatic insufficiency using pancreatic extract in patients with advanced pancreatic cancer: a pilot study (PICNIC).
[So] Source:Support Care Cancer;25(6):1963-1971, 2017 Jun.
[Is] ISSN:1433-7339
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Survival with advanced pancreatic cancer is less than 12 months. Pancreatic exocrine insufficiency may contribute to pancreatic cancer-related cachexia, via nutrient malabsorption. We aimed to determine the feasibility of prescribing pancreatic extract (Creon®) for patients with advanced pancreatic cancer. METHODS: Patients with advanced pancreatic cancer, without frank malabsorption, were randomised in this feasibility study to pancreatic extract 50,000 units with meals and 25,000 units with snacks, or placebo. Standardised dietary advice was given. Anti-cancer and supportive care treatments were permitted. Outcomes included weight, body mass index (BMI), quality of life (QLQC30, PAN26), survival and nutritional assessment (PG-SGA). RESULTS: Eighteen patients were randomised before study closure due to slow recruitment. Baseline characteristics were well matched. Weight loss prior to randomisation was numerically greater in the pancreatic extract group (mean 0.7 vs 2.2 kg). Weight loss was numerically greater in the placebo group, however not significantly. No differences in BMI or nutrition score were seen. Quality of life did not differ between study groups. Median overall survival was 17 (95% CI 8.1-48.7) weeks in the control group, and 67.6 (95% CI 14.1-98.4) weeks in the pancreatic extract group (p = 0.1063). Only 17% (18/106) of potentially eligible patients were recruited, related to patient/family reluctance, rapid clinical deterioration and patients already prescribed pancreatic extract. A moderate pill burden was noted. CONCLUSION: Despite intriguing survival results, this study was not sufficiently feasible to proceed to a fully powered comparative study. A multi-centre study would be required to exclude a significant difference in outcomes.
[Mh] Termos MeSH primário: Caquexia/etiologia
Insuficiência Pancreática Exócrina/terapia
Extratos Pancreáticos/uso terapêutico
Neoplasias Pancreáticas/terapia
Qualidade de Vida/psicologia
[Mh] Termos MeSH secundário: Idoso
Método Duplo-Cego
Estudos de Viabilidade
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias Pancreáticas/mortalidade
Projetos Piloto
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Pancreatic Extracts)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170206
[St] Status:MEDLINE
[do] DOI:10.1007/s00520-017-3602-2


  3 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27593573
[Au] Autor:Usman S; Khan I; Naeem N; Iqbal H; Ali A; Usman S; Salim A
[Ad] Endereço:Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi-75270, Pakistan.
[Ti] Título:Conditioned media trans-differentiate mature fibroblasts into pancreatic beta-like cells.
[So] Source:Life Sci;164:52-59, 2016 Nov 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIM: The study was carried out to evaluate the role of preconditioning strategies on the trans-differentiation of mature fibroblasts (NIH3T3 cells) into insulin producing ß-cells. METHODS: The NIH3T3 cells were treated with dexamethasone (5µM) and pancreatic extract (0.05 and 0.4mg/mL) separately or in combination. The treated cells were analyzed for the morphological changes, and expression of pancreatic genes and proteins by phase contrast microscopy, RT-PCR and flow cytometry/immunocytochemistry, respectively. RESULTS: Treatment of mature fibroblasts with different combinations of dexamethasone and pancreatic extract in the form of conditioned media resulted in comparable morphological changes and expression of certain pancreatic genes and proteins; however, their expression varied with each treatment. Most prominent effect was observed in case of combined treatment which resulted in significant increase (p<0.001) in gene expression levels of insulin, MafA, and Ngn3. Variable pattern was observed in insulin, MafA, Ngn3 and Sca1 expressions at the protein level. CONCLUSION: It is concluded from this study that preconditioning of NIH3T3 cells with conditioned media containing different combinations of dexamethasone and pancreatic extract can induce trans-differentiation of these cells into pancreatic ß-like cells. The conditioned media however, need to be optimized. The study may offer the possibility of improved regeneration of mature cell type that could serve as a future therapeutic option for diabetes.
[Mh] Termos MeSH primário: Diferenciação Celular/efeitos dos fármacos
Meios de Cultivo Condicionados/farmacologia
Fibroblastos/citologia
Fibroblastos/efeitos dos fármacos
Células Secretoras de Insulina/citologia
[Mh] Termos MeSH secundário: Animais
Dexametasona/farmacologia
Seres Humanos
Células Secretoras de Insulina/efeitos dos fármacos
Camundongos
Células NIH 3T3
Pâncreas/citologia
Extratos Pancreáticos/genética
Extratos Pancreáticos/farmacologia
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Culture Media, Conditioned); 0 (Pancreatic Extracts); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170203
[Lr] Data última revisão:
170203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160906
[St] Status:MEDLINE


  4 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26575119
[Au] Autor:Tabur S; Sezen H; Korkmaz H; Ozkaya M; Akarsu E
[Ad] Endereço:Gaziantep University, Gaziantep, Turkey.
[Ti] Título:High Prolidase Levels may be a Marker of Irreversible Extracellular Matrix Changes in Controlled Acromegaly Patients?
[So] Source:Exp Clin Endocrinol Diabetes;124(2):82-6, 2016 Feb.
[Is] ISSN:1439-3646
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:The present study aimed to evaluate the activity of prolidase in controlled acromegaly patients and its association with oxidative stress. 25 acromegalic patients in remission who were followed in our outpatient clinic and 31 healthy controls were enrolled in the study. Serum growth hormone (GH), insulin-like growth factor 1 (IGF-1), total antioxidative status (TAS), total oxidative stress (TOS), total free sulfhydryl (-SH), paraoxonase (PON), arylesterase (ARE), lipid hydroperoxide (LOOH) and prolidase activity levels were measured. Percent ratio of TOS to TAS level was accepted as oxidative stress index (OSI). Serum prolidase activity, TOS, OSI, and LOOH levels were significantly higher in acromegaly patients compared to the healthy control group (p<0.001, p=0.001, p<0.001, and p<0.001, respectively). SH levels were significantly lower in the acromegaly patients compared to the healthy control group (p=0.002). Prolidase activity were positively correlated with TOS, OSI, LOOH and negatively correlated with -SH in patients with acromegaly (r=0.471, p<0.001; r=0.527, p<0.001; r=0.717, p<0.001; r=- 0.516, p<0.001, respectively). These associations were confirmed in the multiple regression analysis (R(2)=0.502, p<0.001). In conclusion, serum prolidase activity and oxidative stress levels were high in controlled acromegaly patients. These results suggest that extracellular matrix changes continue eventhough the disease is controlled, and elevated oxidative stress is involved in the increased prolidase activity in acromegaly patients.
[Mh] Termos MeSH primário: Acromegalia/sangue
Enzimas/sangue
Matriz Extracelular/metabolismo
Estresse Oxidativo
Extratos Pancreáticos/sangue
[Mh] Termos MeSH secundário: Acromegalia/terapia
Adulto
Antioxidantes/metabolismo
Arildialquilfosfatase/sangue
Biomarcadores/sangue
Hidrolases de Éster Carboxílico/sangue
Feminino
Hormônio do Crescimento Humano/sangue
Seres Humanos
Fator de Crescimento Insulin-Like I/metabolismo
Masculino
Meia-Idade
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Biomarkers); 0 (Enzymes); 0 (IGF1 protein, human); 0 (Pancreatic Extracts); 0 (Prolipase); 12629-01-5 (Human Growth Hormone); 67763-96-6 (Insulin-Like Growth Factor I); EC 3.1.1.- (Carboxylic Ester Hydrolases); EC 3.1.1.2 (arylesterase); EC 3.1.8.1 (Aryldialkylphosphatase)
[Em] Mês de entrada:1611
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151118
[St] Status:MEDLINE
[do] DOI:10.1055/s-0035-1564200


  5 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26286496
[Au] Autor:Aeberhard C; Stanga Z; Perrig M; Birrenbach T
[Ad] Endereço:1 Universitätspoliklinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital, Inselspital Bern.
[Ti] Título:["Not to be taken lightly"].
[Ti] Título:Auf die leichte Schulter genommen..
[So] Source:Praxis (Bern 1994);104(17):919-23, 2015 Aug 19.
[Is] ISSN:1661-8157
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Ab] Resumo:A 78 year old patient with type 2 diabetes mellitus was hospitalized because of weakness and poor nutritional status. For several years, he suffered from an unintended weight loss and chronic, pulpy diarrhea. On examination, we found a severe loss of muscle and fat tissue as well as difficulty swallowing. An adequate nutritional therapy with combined parenteral and enteral nutrition was implemented under regular monitoring of electrolytes and volume status, under which the state of health improved noticeably, while steatorrhea improved under substitution of pancreatic enzymes.
[Mh] Termos MeSH primário: Caquexia/etiologia
Diabetes Mellitus Tipo 2/diagnóstico
Insuficiência Pancreática Exócrina/diagnóstico
Metabolismo
Desnutrição Proteico-Calórica/etiologia
Perda de Peso
[Mh] Termos MeSH secundário: Idoso
Caquexia/terapia
Terapia Combinada
Comorbidade
Diabetes Mellitus Tipo 2/terapia
Diagnóstico Diferencial
Nutrição Enteral
Insuficiência Pancreática Exócrina/terapia
Seres Humanos
Masculino
Extratos Pancreáticos/uso terapêutico
Nutrição Parenteral Total
Desnutrição Proteico-Calórica/terapia
[Pt] Tipo de publicação:CASE REPORTS; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pancreatic Extracts)
[Em] Mês de entrada:1512
[Cu] Atualização por classe:150819
[Lr] Data última revisão:
150819
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150820
[St] Status:MEDLINE
[do] DOI:10.1024/1661-8157/a002103


  6 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25513957
[Au] Autor:Borkar N; Li B; Holm R; Håkansson AE; Müllertz A; Yang M; Mu H
[Ad] Endereço:Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Electronic address: nrupa.borkar@sund.ku.dk.
[Ti] Título:Lipophilic prodrugs of apomorphine I: preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media.
[So] Source:Eur J Pharm Biopharm;89:216-23, 2015 Jan.
[Is] ISSN:1873-3441
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Apomorphine, a subcutaneously administered drug for Parkinson's disease with short half-life requires frequent administration leading to patient non-compliance. This study aimed at synthesising and purifying lipophilic diesters of apomorphine, and investigating their in vitro degradation in biorelevant media before and after incorporating them into self-emulsifying drug delivery systems (SEDDS) for oral delivery. Two apomorphine diester prodrugs were synthesised: dilauroyl apomorphine (DLA) and dipalmitoyl apomorphine (DPA). The in vitro enzymatic hydrolysis of diesters was performed using biorelevant media with pancreatin to catalyse the diester degradation. The synthesised and purified diesters were found to be free from reactants as impurities confirmed by LC/MS and NMR. DLA and DPA were degraded into corresponding monoesters and free apomorphine within 5 min after adding pancreatin, leaving about 4% and 28% of the intact diester, respectively. The incorporation of the diesters into SEDDS reduced the enzymatic degradation of diesters. In addition, the chain length of diester and the type of oil used in formulations affected diester hydrolysis. The lipophilic apomorphine diesters were substrates of lipases present in pancreatin, and the degree of diester degradation can be controlled by selecting suitable lipid excipients. Therefore, diesters of apomorphine are promising prodrugs for oral delivery aiming at lymphatic transport.
[Mh] Termos MeSH primário: Apomorfina/química
Pró-Fármacos/química
[Mh] Termos MeSH secundário: Administração Oral
Animais
Sistemas de Liberação de Medicamentos/métodos
Emulsões/química
Ésteres/química
Hidrólise
Lipídeos/química
Extratos Pancreáticos/química
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Emulsions); 0 (Esters); 0 (Lipids); 0 (Pancreatic Extracts); 0 (Prodrugs); N21FAR7B4S (Apomorphine)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:150309
[Lr] Data última revisão:
150309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141217
[St] Status:MEDLINE


  7 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25448594
[Au] Autor:Pérez RL; Loureiro DB; Nerli BB; Tubio G
[Ad] Endereço:Departamento de Químico-Física, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Argentina.
[Ti] Título:Optimization of pancreatic trypsin extraction in PEG/citrate aqueous two-phase systems.
[So] Source:Protein Expr Purif;106:66-71, 2015 Feb.
[Is] ISSN:1096-0279
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Enzyme extraction using aqueous two-phase systems (ATPS) has been increasingly used as a primary recovery technique which integrates the clarification, concentration and partial purification of important biomolecules from their natural source in a single step. The goal of this work was to optimize the extraction of trypsin from pancreas homogenate with polyethylene glycol and sodium citrate (PEG/NaCit) ATPS by using the tools of experimental design. The variables NaCl concentration - added inert salt -, the top/bottom phase volume ratio - Vr - and the biomass loaded into the system - in percentage - were selected as the main factors in the trypsin extraction. The yield (%) and the purification factor of trypsin were considered the responses to be optimized. The central composite design and the response surface analysis proved to be suitable tools for a quick and efficient study. As a result, the optimal extraction conditions in PEG3350/NaCit system were 3.34% wt/wt for NaCl concentration, a biomass load which represented 9.30% wt/wt of the total ATPS mass and 6.37 top/bottom volume ratio giving a purification factor of 2.55 and a yield of 99.7% in top phase.
[Mh] Termos MeSH primário: Bioquímica/métodos
Citratos/química
Pâncreas/enzimologia
Polietilenoglicóis/química
Tripsina/isolamento & purificação
[Mh] Termos MeSH secundário: Animais
Bovinos
Concentração de Íons de Hidrogênio
Extratos Pancreáticos/metabolismo
Análise de Regressão
Reprodutibilidade dos Testes
Água
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Citrates); 0 (Pancreatic Extracts); 059QF0KO0R (Water); 1Q73Q2JULR (sodium citrate); 30IQX730WE (Polyethylene Glycols); EC 3.4.21.4 (Trypsin)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141203
[St] Status:MEDLINE


  8 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25342478
[Au] Autor:Jannin V; Dellera E; Chevrier S; Chavant Y; Voutsinas C; Bonferoni C; Demarne F
[Ad] Endereço:a Gattefossé SAS , Saint-Priest , France and.
[Ti] Título:In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract.
[So] Source:Drug Dev Ind Pharm;41(10):1582-8, 2015.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLC) are lipid nanocarriers aimed to the delivery of drugs characterized by a low bioavailability, such as poorly water-soluble drugs and peptides or proteins. The oral administration of these lipid nanocarriers implies the study of their lipolysis in presence of enzymes that are commonly involved in dietary lipid digestion in the gastrointestinal tract. In this study, a comparison between two methods was performed: on one hand, the lipase/co-lipase assay, commonly described in the literature to study the digestion of lipid nanocarriers, and on the other hand, the lipolysis test using porcine pancreatic extract and the pH-stat apparatus. This pancreatic extract contains both the pancreatic lipase and carboxyl ester hydrolase (CEH) that permit to mimic in a biorelevant manner the duodenal digestive lipolysis. The test was performed by means of a pH-stat apparatus to work at constant pH, 5.5 or 6.25, representing respectively the fasted or fed state pH conditions. The evolution of all acylglycerol entities was monitored during the digestion by sampling the reaction vessel at different time points, until 60 min, and the lipid composition of the digest was analyzed by gas chromatography. SLN and NLC systems obtained with long-chain saturated acylglycerols were rapidly and completely digested by pancreatic enzymes. The pH-stat titration method appears to be a powerful technique to follow the digestibility of these solid lipid-based nanoparticles.
[Mh] Termos MeSH primário: Carboxilesterase/química
Lipase/química
Lipídeos/química
Nanopartículas/química
Extratos Pancreáticos/química
[Mh] Termos MeSH secundário: Administração Oral
Animais
Disponibilidade Biológica
Digestão
Liberação Controlada de Fármacos
Concentração de Íons de Hidrogênio
Lipólise
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Lipids); 0 (Pancreatic Extracts); EC 3.1.1.1 (Carboxylesterase); EC 3.1.1.3 (Lipase)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150914
[Lr] Data última revisão:
150914
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141025
[St] Status:MEDLINE
[do] DOI:10.3109/03639045.2014.972412


  9 / 678 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25242743
[Au] Autor:Dodge JA
[Ad] Endereço:Swansea University, UK. Electronic address: j.a.dodge@btinternet.com.
[Ti] Título:Pancreatic enzymes and Fibrosing Colonopathy.
[So] Source:J Cyst Fibros;14(1):153, 2015 Jan.
[Is] ISSN:1873-5010
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Doenças do Colo/induzido quimicamente
Doenças do Colo/patologia
Extratos Pancreáticos/efeitos adversos
Pancreatina/efeitos adversos
[Mh] Termos MeSH secundário: Fibrose Cística/tratamento farmacológico
Fibrose/induzido quimicamente
Fibrose/patologia
Seres Humanos
Extratos Pancreáticos/uso terapêutico
Pancreatina/uso terapêutico
Pancrelipase/efeitos adversos
Pancrelipase/uso terapêutico
Ácidos Polimetacrílicos/efeitos adversos
Ácidos Polimetacrílicos/uso terapêutico
Medição de Risco
Reino Unido
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Pancreatic Extracts); 0 (Polymethacrylic Acids); 25086-15-1 (methylmethacrylate-methacrylic acid copolymer); 53608-75-6 (Pancrelipase); 8049-47-6 (Pancreatin)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140923
[St] Status:MEDLINE


  10 / 678 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:25417707
[Au] Autor:Pezzilli R
[Ad] Endereço:Pancreas Unit, Department of Digestive Diseases, Sant'Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy. raffaele.pezzilli@aosp.bo.it.
[Ti] Título:Exocrine pancreas involvement in celiac disease: a review.
[So] Source:Recent Pat Inflamm Allergy Drug Discov;8(3):167-72, 2014.
[Is] ISSN:1872-213X
[Cp] País de publicação:United Arab Emirates
[La] Idioma:eng
[Ab] Resumo:UNLABELLED: There are numerous studies in the literature regarding the involvement of intestinal as well as extra intestinal organs during the course of celiac disease, and there is accumulating evidence regarding the pancreatic changes caused by this pathology. METHOD: The literature on the relationship between celiac disease and pancreatic involvement has been extensively reviewed. RESULTS: Exocrine pancreatic involvement regards both the function and the morphology of the exocrine pancreas, and superimposed or more severe clinical changes seem to be related to the nutritional disturbances caused by celiac disease or by the disease itself. Patients with celiac disease may also develop a chronic pancreatitis more frequently than in general population both the intestinal and the extraintestinal manifestations of celiac disease. CONCLUSIONS: Fecal elastase 1-determination in celiacs may be useful in detecting and curing exocrine pancreatic insufficiency especially in patients with a new diagnosis of celiac disease or in those with refractory diarrhea. Few patents on pancreatic extracts are also briefly described.
[Mh] Termos MeSH primário: Doença Celíaca/complicações
Insuficiência Pancreática Exócrina/etiologia
Pâncreas Exócrino/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Doença Celíaca/fisiopatologia
Insuficiência Pancreática Exócrina/epidemiologia
Fezes/enzimologia
Seres Humanos
Elastase Pancreática/metabolismo
Extratos Pancreáticos/administração & dosagem
Pancreatite Crônica/epidemiologia
Pancreatite Crônica/etiologia
Patentes como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Pancreatic Extracts); EC 3.4.21.36 (Pancreatic Elastase)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:150120
[Lr] Data última revisão:
150120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141125
[St] Status:MEDLINE



página 1 de 68 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde